Humanigen seeks FDA approval for COVID-19 drug

By The Science Advisory Board staff writers

May 28, 2021 -- Humanigen requested an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to use its drug lenzilumab in hospitalized COVID-19 patients.

This application follows positive results from the LIVE-AIR phase III clinical trial that showed lenzilumab improved the likelihood of survival without ventilation in newly hospitalized COVID-19 patients.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.